IP Group Plc (LON:IPO)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 592.78M +44.3% |
| Revenue (ttm) | 79.80M |
| Net Income | 66.80M |
| EPS | 0.07 |
| Shares Out | 883.43M |
| PE Ratio | 9.45 |
| Forward PE | 11.94 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,873,660 |
| Open | 67.10 |
| Previous Close | 67.10 |
| Day's Range | 66.50 - 68.47 |
| 52-Week Range | 42.30 - 69.40 |
| Beta | 1.26 |
| Analysts | Strong Buy |
| Price Target | 105.00 (+57.19%) |
| Earnings Date | Jun 17, 2026 |
About IP Group
IP Group Plc is a private equity and venture capital firm specializing in seed/startup, early venture, emerging growth, mature, mid venture, late venture, incubation, mezzanine in growth capital companies. It prefers to invest in energy, materials, healthcare, information technology, communication services, utilities, life sciences, deeptech, cleantech, chemicals, science and innovation companies. The firm prefers to invest in Europe, typically invests in companies based in or willing to relocate to North East England. It firm prefers to invest... [Read more]
Financial Performance
Financial StatementsNews
IP Group price target raised to 110 GBp from 103 GBp at Deutsche Bank
Deutsche Bank raised the firm’s price target on IP Group (IPZYF) to 110 GBp from 103 GBp and keeps a Buy rating on the shares.
IP Group Earnings Call Transcript: H2 2025
NAV per share grew 13% year-over-year, driven by a major royalty interest in Pfizer's obesity drug, strong cash exits, and disciplined buybacks. Portfolio companies raised GBP 900 million in third-party capital, and the group remains focused on deep tech, clean tech, and life sciences.
IP Group Annual report: H2 2025
IP Group has published its H2 2025 annual report on March 17, 2026.
IP Group Slides: H2 2025
IP Group has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 17, 2026.
IP Group Annual report: H2 2025
IP Group has published its H2 2025 annual report on March 17, 2026.
IP Group Earnings Call Transcript: H2 2025
NAV per share grew 13% year-over-year, driven by a major royalty interest in Pfizer's obesity drug, strong cash exits, and disciplined buybacks. Portfolio companies raised GBP 900 million in third-party capital, and the group remains focused on deep tech, clean tech, and life sciences.
IP Group Annual report: H2 2025
IP Group has published its H2 2025 annual report on March 17, 2026.
IP Group Slides: H2 2025
IP Group has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 17, 2026.
IP Group Annual report: H2 2025
IP Group has published its H2 2025 annual report on March 17, 2026.
IP Group price target lowered to 103 GBp from 114 GBp at Deutsche Bank
Deutsche Bank lowered the firm’s price target on IP Group (IPZYF) to 103 GBp from 114 GBp and keeps a Buy rating on the shares.
IP Group Earnings Call Transcript: H1 2025
Strong H1 progress with GBP 30m in exits, robust cash position, and NAV per share rising to GBP 1. Hinge Health IPO and Oxford Nanopore outperformance drove value, while buybacks accelerated. Confident in GBP 250m exit target by 2027 and securing new scale-up mandates.
IP Group Quarterly report: H1 2025
IP Group has published its H1 2025 quarterly earnings report on September 17, 2025.
IP Group Slides: H1 2025
IP Group has posted slides in relation to its H1 2025 quarterly earnings report, which was published on September 17, 2025.
IP Group Earnings Call Transcript: H1 2025
Strong H1 progress with GBP 30m in exits, robust cash position, and NAV per share rising to GBP 1. Hinge Health IPO and Oxford Nanopore outperformance drove value, while buybacks accelerated. Confident in GBP 250m exit target by 2027 and securing new scale-up mandates.
IP Group Quarterly report: H1 2025
IP Group has published its H1 2025 quarterly earnings report on September 17, 2025.
IP Group Slides: H1 2025
IP Group has posted slides in relation to its H1 2025 quarterly earnings report, which was published on September 17, 2025.
IP Group Transcript: CMD 2025
The event outlined a strategy focused on leveraging the U.K.'s scientific strengths to build and scale deep tech businesses, addressing global mega trends in energy, healthcare, and digitalization. With strong government support and a robust investment pipeline, the group is well positioned for growth and value creation.
IP Group Transcript: CMD 2025
The event outlined a strategy focused on leveraging the U.K.'s scientific strengths to build and scale deep tech businesses, addressing global mega trends in energy, healthcare, and digitalization. With strong government support and a robust investment pipeline, the group is well positioned for growth and value creation.
IP Group Transcript: AGM 2025
The meeting highlighted record cash realizations, a strong cash position, and decisive cost reductions. Strategic focus remains on addressing the NAV discount, expanding buybacks, and building scale-up capital, with all AGM resolutions passed and robust shareholder engagement throughout.
IP Group Transcript: AGM 2025
The meeting highlighted record cash realizations, a strong cash position, and decisive cost reductions. Strategic focus remains on addressing the NAV discount, expanding buybacks, and building scale-up capital, with all AGM resolutions passed and robust shareholder engagement throughout.
IP Group Earnings Call Transcript: H2 2024
Cash exits reached GBP 183 million in 2024, outpacing a sluggish VC market, while accelerated buybacks retired over 10% of shares. Despite a 15% NAV per share decline due to write-downs in key holdings, cost reductions and a strong pipeline position the group for future growth.
IP Group Annual report: H2 2024
IP Group has published its H2 2024 annual report on March 25, 2025.
IP Group Annual report: H2 2024
IP Group has published its H2 2024 annual report on March 25, 2025.
IP Group Slides: H2 2024
IP Group has posted slides in relation to its H2 2024 quarterly earnings report, which was published on March 25, 2025.
IP Group Earnings Call Transcript: H1 2024
Portfolio exits accelerated in H1 2024, enabling significant capital returns despite a 9% NAV per share decline driven by Nanopore. Cost reductions and a strong cash position support further buybacks, while momentum is building for additional exits and value creation in H2.